MD Anderson Cancer Center and Exscientia plc formed a strategic collaboration to align the drug discovery and development expertise of MD Anderson with the patient-centric artificial intelligence capabilities of Exscientia in order to advance novel small-molecule oncology therapies.
Organon launched the distribution of Ontruzant, a biosimilar of Herceptin, in Canada, providing an additional treatment option for Canadian adults diagnosed with early breast cancer, metastatic breast cancer, and metastatic gastric cancer.
Gregory Reaman was named scientific director of the NCI Childhood Cancer Data Initiative. The initiative represents a national commitment to harnessing and sharing data in ways to make faster progress in childhood cancers.
Fox Chase Cancer Center, Sylvester Comprehensive Cancer Center, and Pfizer’s Institute of Translational Equitable Medicine formed a collaboration to launch a cancer genomics study to characterize novel genetic, molecular, and social determinants of cancer across populations of African ancestry.
UPMC has partnered with Dragan Primorac, a physician and founder and chairman of St. Catherine Specialty Hospital, to expand cancer services in Croatia.
More than 50 cancer organizations to issue a call to action urging individuals, providers, and insurers to increase access to and utilization of low-dose CT scans for those at high risk for lung cancer.
Friends and colleagues of Theresa Mays have established the Theresa Mays Endowed Merit Award to promote the education and advancement of oncology research for pharmacists.
FDA has approved Libtayo (cemiplimab-rwlc) in combination with platinum-based chemotherapy for adult patients with advanced non-small cell lung cancer with no EGFR, ALK, or ROS1 aberrations.
FDA has approved Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer with no sensitizing EGFR mutation or anaplastic lymphoma kinase genomic tumor aberrations.
FDA approved Adcetris (brentuximab vedotin) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients 2 years of age and older with previously untreated high risk classical Hodgkin lymphoma. This is the first pediatric approval for Adcetris.
